Difference between revisions of "Streptozocin (Zanosar)"
Jump to navigation
Jump to search
m |
m |
||
| (19 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Nitrosourea, alkylates DNA and RNA, antibiotic oncologic, mechanism not fully understood. Streptozocin has been observed to have greater toxicity to pancreatic islet beta cells, possibly because streptozocin can be transported into beta cells via the glucose transport protein GLUT2.<ref name="insert">[http://zanosar.com/files/Keocyt_Zanosar_SPC_2010.pdf Streptozocin (Zanosar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/streptozocin.pdf Streptozocin (Zanosar) package insert (locally hosted backup)]</ref><ref>[http://zanosar.com/ Zanosar manufacturer's website]</ref> | Class/mechanism: Nitrosourea, alkylates DNA and RNA, antibiotic oncologic, mechanism not fully understood. Streptozocin has been observed to have greater toxicity to pancreatic islet beta cells, possibly because streptozocin can be transported into beta cells via the glucose transport protein GLUT2.<ref name="insert">[http://zanosar.com/files/Keocyt_Zanosar_SPC_2010.pdf Streptozocin (Zanosar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/streptozocin.pdf Streptozocin (Zanosar) package insert (locally hosted backup)]</ref><ref>[http://zanosar.com/ Zanosar manufacturer's website]</ref> | ||
<br>Route: IV | <br>Route: IV | ||
| − | <br>Extravasation: [[ | + | <br>Extravasation: [[irritant]] |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Neuroendocrine | + | *[[Adrenocortical carcinoma]] |
| + | *[[Neuroendocrine tumor]] | ||
| + | *[[Pancreatic NET]] | ||
| + | ==Diseases for which it was used== | ||
| + | *[[Classical Hodgkin lymphoma_-_historical|Hodgkin lymphoma]] | ||
| + | *[[Pancreatic cancer_-_historical|Pancreatic cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 17: | Line 20: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1982-05-07: Initial FDA approval for the treatment of metastatic [[Pancreatic NET|islet cell carcinoma of the pancreas]]. Responses have been obtained with both functional and nonfunctional carcinomas. Because of its inherent renal toxicity, therapy with this drug should be limited to patients with symptomatic or progressive metastatic disease. ''(No supporting studies are cited)'' |
| + | ==History of changes in EMA indication== | ||
| + | *1982-05-07: EURD | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2014-09-26: Initial approval for the treatment of [[Pancreatic NET|neuroendocrine tumors of the pancreas]] and gastrointestinal tract. | ||
| + | ==Also known as== | ||
| + | *'''Generic name:''' STZ | ||
| + | *'''Brand name:''' Zanosar | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Intravenous medications]] |
| + | |||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
| − | [[Category: | + | [[Category:Nitrosoureas]] |
| + | [[Category:Adrenocortical carcinoma medications]] | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
| + | [[Category:Pancreatic NET medications]] | ||
| + | |||
| + | [[Category:Classical Hodgkin lymphoma medications (historic)]] | ||
| + | [[Category:Pancreatic cancer medications (historic)]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1982]] |
| + | [[Category:EMA approved in 1982]] | ||
| + | [[Category:PMDA approved in 2014]] | ||
Revision as of 01:04, 7 November 2023
General information
Class/mechanism: Nitrosourea, alkylates DNA and RNA, antibiotic oncologic, mechanism not fully understood. Streptozocin has been observed to have greater toxicity to pancreatic islet beta cells, possibly because streptozocin can be transported into beta cells via the glucose transport protein GLUT2.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Diseases for which it was used
Patient drug information
- Streptozocin (Zanosar) patient drug information from manufacturer[4]
- Streptozocin (Zanosar) patient drug information (Chemocare)[5]
- Streptozocin (Zanosar) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 1982-05-07: Initial FDA approval for the treatment of metastatic islet cell carcinoma of the pancreas. Responses have been obtained with both functional and nonfunctional carcinomas. Because of its inherent renal toxicity, therapy with this drug should be limited to patients with symptomatic or progressive metastatic disease. (No supporting studies are cited)
History of changes in EMA indication
- 1982-05-07: EURD
History of changes in PMDA indication
- 2014-09-26: Initial approval for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract.
Also known as
- Generic name: STZ
- Brand name: Zanosar
References
- ↑ 1.0 1.1 Streptozocin (Zanosar) package insert
- ↑ Streptozocin (Zanosar) package insert (locally hosted backup)
- ↑ Zanosar manufacturer's website
- ↑ Streptozocin (Zanosar) patient information from manufacturer
- ↑ Streptozocin (Zanosar) patient drug information (Chemocare)
- ↑ Streptozocin (Zanosar) patient drug information (UpToDate)
Categories:
- Drugs
- Intravenous medications
- Alkylating agents
- Nitrosoureas
- Adrenocortical carcinoma medications
- Neuroendocrine tumor medications
- Pancreatic NET medications
- Classical Hodgkin lymphoma medications (historic)
- Pancreatic cancer medications (historic)
- FDA approved in 1982
- EMA approved in 1982
- PMDA approved in 2014